Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets. Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments,… Read More
Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in… Read More
Bristol Myers Squibb has completed its acquisition of RayzeBio for approximately $4.1 billion, adding radiopharmaceutical therapeutics (RPTs) to its pipeline. Chris Boerner, Chief Executive Officer, Bristol Myers Squibb, said: “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support… Read More
